HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983-2015.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 17 04 2024
accepted: 30 09 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

HIV replication leads to a change in lymphocyte phenotypes that impairs immune protection against opportunistic infections. We examined current HIV replication as an independent risk factor for tuberculosis (TB). We included people living with HIV from 25 European cohorts 1983-2015. Individuals <16 years or with previous TB were excluded. Person-time was calculated from enrolment (baseline) to the date of TB diagnosis or last follow-up information. We used adjusted Poisson regression and general additive regression models. We included 272,548 people with a median follow-up of 5.9 years (interquartile range [IQR] 2.3-10.9). At baseline, the median CD4 cell count was 355 cells/μL (IQR 193-540) and the median HIV-RNA level 22,000 copies/mL (IQR 1,300-103,000). During 1,923,441 person-years of follow-up, 5,956 (2.2%) people developed TB. Overall, TB incidence was 3.1 per 1,000 person-years (95% confidence interval [CI] 3.02-3.18) and was four times higher in patients with HIV-RNA levels of 10,000 compared with levels <400 copies/mL in any CD4 stratum. CD4 and HIV-RNA time-updated analyses showed that the association between HIV-RNA and TB incidence was independent of CD4. The TB incidence rate ratio for people born in TB-endemic countries compared with those born in Europe was 1.8 (95% CI 1.5-2.2). Our results indicate that ongoing HIV replication (suboptimal HIV control) is an important risk factor for TB, independent of CD4 count. Those at highest risk of TB are people from TB-endemic countries. Close monitoring and TB preventive therapy for people with suboptimal HIV control is important.

Identifiants

pubmed: 39453919
doi: 10.1371/journal.pone.0312035
pii: PONE-D-24-10899
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0312035

Informations de copyright

Copyright: © 2024 Atkinson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Andrew Atkinson (A)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Infectious Diseases Division, Washington University School of Medicine in St Louis, St Louis, MO, United States of America.

David Kraus (D)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Mathematics and Statistics, Masaryk University, Brno, Czech Republic.

Nicolas Banholzer (N)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Jose M Miro (JM)

Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.
CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.

Peter Reiss (P)

Stichting HIV Monitoring, Amsterdam, The Netherlands.
Amsterdam UMC, location University of Amsterdam, Global Health, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.

Ole Kirk (O)

Centre of Excellence for Health, Immunity and Infections (CHIP), Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Cristina Mussini (C)

Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.

Philippe Morlat (P)

ISPED, INSERM Bordeaux Population Health Research Center, Team PHARes, UMR 1219, University of Bordeaux, Bordeaux, France.
Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bordeaux (CHU), Bordeaux, France.

Daria Podlekareva (D)

Centre of Excellence for Health, Immunity and Infections (CHIP), Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Department of Respiratory and Infectious Diseases, Copenhagen University Hospital, Bispebjerg, Denmark.

Alison D Grant (AD)

Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Africa Health Research Institute, School of Laboratory Medicine & Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, KwaZulu-Natal, South Africa.

Caroline Sabin (C)

Institute for Global Health, University College London, London, United Kingdom.

Marc van der Valk (M)

Stichting HIV Monitoring, Amsterdam, The Netherlands.
Amsterdam UMC, location University of Amsterdam, Global Health, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
Department of Infectious Diseases, Location University of Amsterdam, Amsterdam Institute for Immunology & Infectious Diseases, Infectious Diseases Program, Amsterdam UMC, Amsterdam, The Netherlands.

Vincent Le Moing (V)

CHU de Montpellier, Université de Montpellier, Montpellier, France.

Laurence Meyer (L)

Department of Public Health and Epidemiology, AP-HP, Bicêtre Hospital, INSERM CESP U1018, Paris-Saclay University, Le Kremlin Bicêtre, France.

Remonie Seng (R)

Department of Public Health and Epidemiology, AP-HP, Bicêtre Hospital, INSERM CESP U1018, Paris-Saclay University, Le Kremlin Bicêtre, France.

Antonella Castagna (A)

Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Niels Obel (N)

Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Anastasia Antoniadou (A)

University General Hospital Attikon, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Dominique Salmon (D)

Department of Infectious Diseases, Institut Fournier, Paris, France.

Marcel Zwahlen (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Matthias Egger (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Stephane de Wit (S)

Department of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Hansjakob Furrer (H)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.

Lukas Fenner (L)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH